2605 related articles for article (PubMed ID: 20010090)
21. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
22. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
23. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
24. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
25. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Ocvirk J; Brodowicz T; Wrba F; Ciuleanu TE; Kurteva G; Beslija S; Koza I; Pápai Z; Messinger D; Yilmaz U; Faluhelyi Z; Yalcin S; Papamichael D; Wenczl M; Mrsic-Krmpotic Z; Shacham-Shmueli E; Vrbanec D; Esser R; Scheithauer W; Zielinski CC
World J Gastroenterol; 2010 Jul; 16(25):3133-43. PubMed ID: 20593498
[TBL] [Abstract][Full Text] [Related]
27. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
28. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
29. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
30. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
32. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello F; Normanno N; Maiello E; Martinelli E; Troiani T; Pisconti S; Giuliani F; Barone C; Cartenì G; Rachiglio AM; Montesarchio V; Tonini G; Rizzi D; Cinieri S; Bordonaro R; Febbraro A; De Vita F; Orditura M; Fenizia F; Lambiase M; Rinaldi A; Tatangelo F; Botti G; Colucci G
Ann Oncol; 2014 Sep; 25(9):1756-1761. PubMed ID: 24942275
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
34. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
35. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
36. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L; Störkel S; Kerr KM; Van Cutsem E; Pirker R; Hirsch FR; Vermorken JB; von Heydebreck A; Esser R; Celik I; Ciardiello F
Eur J Cancer; 2013 Apr; 49(6):1161-8. PubMed ID: 23265711
[TBL] [Abstract][Full Text] [Related]
38. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
39. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract][Full Text] [Related]
40. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
Rodríguez J; Zarate R; Bandres E; Boni V; Hernández A; Sola JJ; Honorato B; Bitarte N; García-Foncillas J
Eur J Cancer; 2012 Aug; 48(12):1774-80. PubMed ID: 22305465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
